Macitentan

Especificaciones

441798-33-0Número CAS

810-007-8Número CE

5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amineNombre IUPAC

C19H20Br2N6O4SFórmula química

588.3 g/molPeso molecular

Macitentan; 441798-33-0; Opsumit; ACT-064992; Actelion-1; ACT 064992; ACT064992; macitentanum; Z9K9Y9WMVL; CHEBI:76607; DTXSID50196063; OPSYNVI COMPONENT MACITENTAN; {[5-(4-BROMOPHENYL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]SULFAMOYL}(PROPYL)AMINE; n-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-n'-propylaminosulfonamide; N-(5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXI)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-N'-propylsulfamide; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'-propylsulfuric diamide; ((5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfamoyl)(propyl)amine; N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-N'-propylsulfuric diamide; RefChem:58979; C02KX04; DTXCID60118554; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide; MFCD17167076; C19H20Br2N6O4S; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'- propylsulfamide; Macitentan [INN]; Macitentan [USAN:INN]; UNII-Z9K9Y9WMVL; Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl-; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; ACT 064992; Macitentan; Opsumit; Propylsulfamic acid N-[5-(4-bromophenyl)-6-[2-[(5-bromopyrimidin-2-yl)oxy]ethoxy]pyrimidin-4-yl]amide; Opsumit (TN); Macitentan (Standard); MACITENTAN [MI]; MACITENTAN [JAN]; Macitentan (JAN/USAN); MACITENTAN [USAN]; MACITENTAN [VANDF]; A1D5I; MACITENTAN [WHO-DD]; MLS006011174; GTPL7352; Macitentan - Bio-X trade mark; orb1225044; orb1305317; SCHEMBL1445625; CHEMBL2103873; MACITENTAN [ORANGE BOOK]; SCHEMBL29378853; EX-A544; JGCMEBMXRHSZKX-UHFFFAOYSA-N; GLXC-90056; HMS3653N06; HMS3747E09; HMS5086O05; cas:441798-33-0;Macitentan; IAC42805; BDBM50395626; EBC-27358; HY-14184R; AKOS024463406; CCG-270155; CS-0686; DB08932; FM65071; SB14841; Macitentan (Actelion-1,ACT-064992); NCGC00346456-01; NCGC00346456-04; NCGC00346456-05; AC-30102; AS-74590; BM162771; HY-14184; SMR004702943; Macitentan (Actelion-1,ACT-064992)?; DB-070519; NS00072551; SW219473-1; ACT 064992; ACT-064992; D10135; Opsynvi (combination of macitentan + tadalafil); EN300-7404089; Q6724151; BRD-K48812570-001-02-3; BRD-K48812570-001-03-1; 5-(p-Bromophenyl)-6-[2-(5-bromo-2-pyrimidinyloxy)ethoxy]-4-(propylaminosulfonylamino)pyrimidine; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl-; Macitentan MicronizedSinónimos